Published in Cancer Weekly, June 24th, 2003
The results, presented in a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, indicated that TNFerade, when used in combination with standard chemotherapy and radiation, was well-tolerated at the two dose levels evaluated to date.
Local control or stabilization of the treated tumors was also seen in 11 of the 17 evaluable patients (65%) as reported by an independent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.